Castration-Resistant Prostate Cancer

P2, N=30, Not yet recruiting, Deepak Kilari | Trial completion date: Dec 2027 --> Jul 2029 | Trial primary completion date: Dec 2026 --> Jul 2028

These findings suggest that combining tumor-sensitizing therapies with selective T-cell activation may represent a broader strategy to overcome immune exclusion in solid tumors. Together, these results provide mechanistic rationale for clinical evaluation of olaparib in combination with STAR0602 in patients with mCRPC who have progressed on androgen deprivation therapy.

P1, N=30, Not yet recruiting, University of Texas Southwestern Medical Center

While next-generation androgen receptor signaling inhibitors (ARSIs), such as enzalutamide and abiraterone, have revolutionized CRPC treatment, resistance to these therapies remains a significant challenge, rendering the disease incurable. Compelling evidence further suggests that combining PLK1 inhibition with paclitaxel could serve as an effective therapeutic strategy to overcome resistance in CRPC by targeting microtubule dynamics. This review examines the mechanistic role and broader implications of PLK1 in CRPC treatment, offering valuable insights into potential combination therapies to improve efficacy and patient outcomes.

For castration-resistant prostate cancer, cabazitaxel and second-generation androgen receptor inhibitors are the major therapeutic approaches. We also review several non-canonical treatment strategies.

The survey results suggest that treatment selection of Japanese doctors may differ from those of the APCCC24. More extensive surveys are needed for further discussion on the treatment selection for patients with advanced prostate cancer in Japan.

P=N/A, N=1067, Not yet recruiting, Novartis Pharmaceuticals

P1/2, N=152, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P1, N=36, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting

P=N/A, N=17111, Not yet recruiting, Novartis Pharmaceuticals

P1, N=33, Active, not recruiting, Novartis Pharmaceuticals | Phase classification: P1/2 --> P1 | Trial completion date: Nov 2029 --> Mar 2031 | Trial primary completion date: Nov 2026 --> Mar 2031

Although PARP inhibitor olaparib has been approved for metastatic CRPC patients bearing BRCA1/2 mutations, its application is confined to this specific patient subpopulation...Their synergistic effect was confirmed in ex vivo explants from human PCa specimens. Our findings demonstrated CDK9 as a master regulator of BRCAness and proposed targeting CDK9 as a potential strategy to sensitize CRPC patients without BRCA1/2 mutations to PARP inhibition.